Lawrence Wagman, M.D.
- Breast Cancer
- Melanoma
- Sarcoma
- Pancreatic Cancer
- Liver Cancer
- Bile Duct Cancer
- Clinical Professor, Division of Surgical Oncology, Department of Surgery
- Regional Medical Director, Inland Empire
- Regional Medical Director, South Bay (Torrance)
Education & Experience
1978, M.D., Columbia University-College of Physicians and Surgeons, New York, NY
1974, B.A., Biology, State University of New York, Buffalo, NY
1980-1982, Surgical Oncology, Clinical Associate, National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD
1984-1985, Administrative Chief Resident, Medical College of Virginia, Richmond, VA
1978-1979, 1982-1984, Categorical Surgery, Medical College of Virginia, Richmond, VA
2018-present, Surgical Oncologist and Clinical Professor, Division of Surgical Oncology, Department of Surgery, City of Hope, Upland, CA
2018-present, Physician Regional Medical Director, City of Hope, Inland Empire and South Bay, CA
1991-2005, Chairman, Division of Surgery, City of Hope, Duarte, CA
1993-1997, Medical Director, Ambulatory Care Services, City of Hope, Duarte, CA
1991-2003, Director, Department of General Oncologic Surgery, City of Hope, Duarte, CA
1987-1992, Senior Surgeon, Department of General Oncologic Surgery, City of Hope, Duarte, CA
1985-1987, Staff Surgeon, Department of General Oncologic Surgery, City of Hope, Duarte, CA
2008-2018, Executive Medical Director, The Center for Cancer Prevention and Treatment, St. Joseph Hospital, Orange, CA
2009-2017, Program Director-Liver, Bile Duct, and Pancreas Program, St. Joseph Hospital, Orange, CA
1993-2018, Associate Clinical Professor, Department of Surgery, University of California-San Diego, San Diego, CA
1989-1993, Assistant Clinical Professor, Department of Surgery, University of California-San Diego, San Diego, CA
1991-1999, Director, Surgical Oncology Training Program
Awards & Memberships
Awards
2008-2019, Best Doctors in America
2014-2017, Top Doctors, Orange Coast Magazine
2005-2017, America’s Top Doctors for Cancer
2009-2017, America’s Top Doctors
2015-2021, Southern California Super Doctors
2008-2023 Southern California's Best Doctors
Publications
- Chen LJ, Otis S, Moeller KJ, Wagman LD. Improvement in Patient Reported Outcomes Following Red Blood Cell Transfusions in an Ambulatory Oncology Population – A Quality Study.
- Wagman BH, Chaudhary R, Karlin E, El-Bayar H, Wagman LD. Surgical radiofrequency ablation of hepatic lesions: Local and non-local recurrence.
- Cahan B, Leong L, Wagman L, et al. Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. Cancer Biother Radiopharm. 2017 Sep;32(7):258-265
- Wagman B, Chaudhary R, Karlin E, Wagman LD. (2017) Sarcoma Suspicious: Extramedullary Hematopoiesis and Heterotopic Bone. Arc Cas Rep CMed 3(3):145. 2017 Sep 28
- Bhandari T, BabaranW, Forouzannia A, Williams V, Harness J, Carpenter M, Maher G, Khanijou R, Wagman B, Wagman LD, Ash R. Comparison of Toxicity and Cosmesis Outcomes of Single Fraction (SF) IORT and Hypofractionated Radiotherapy with IORT Boost (HfB) in Early Stage Breast Cancer. Brachytherapy. 2017 Oct 9. pii: S1538-4721(17)30456-7. DOI: 10.1016/j.brachy.2017.09.002. [Epub ahead of print]
- Pop V, Dobrea L, Brown S, Gonzalez N, Alquitela R, Bati R, French M, LaBeet S, Lima M, Trujillo Castro, V, Walter N, Barrett SM, Sassoon A, Wagman LD. A Model for Tissue Banking in the Community Setting. Oncology Issues. 2017 Jul-Aug; 37-48. http://www.accc-cancer.org/oncology_issues/articles/JA17/JA17-A-Model-for-Tissue-Bankingin-the-Community-Setting.pdf
- Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, et al. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget. 2016 Oct 18;7(42):68206-68228. DOI: 10.18632/oncotarget.11910.
- Carandang M, Babaran W, Wagman LD, Nacpil L, Lara T, Castro N, Greene S. Compliance with Breast Cancer Post-Therapy Surveillance. Oncology Issues 2016;31(6):34-41
- Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome. Gynecol Oncol Rep, 2015 Feb 26;12:31-3.
- Wagman LD. Hepatocellular Cancer, cholangiocarcinoma, and metastatic tumors of the liver. Surg Oncol clin N. Am 2015 Jan;24(1):xiii-xiv.
- Wagman LD, Casciari R, Maurice J, et al. How Lean Methodology Can Improve Molecular Testing Processes in Advanced NSCLC. Oncology Issues 2015;30(1):34-43.
- Wagman LD. In discussion of: Carlson RH. The changing face and gaining acceptance of palliative surgery. Oncology Times 2014; 36(22):65-67.
- Wagman LD. Importance of response to neoadjuvant therapy in patients with liver-limited mCRC when the intent is resection and/or ablation. Clin Colorectal Cancer. 2013 Dec;12(4):223-32
- Wagman LD. Hepatic Artery Infusion: Still an Option? Ann Surg Oncol. 2013 May 21.
- Ash R, Williams VL, Wagman LD, Forouzannia A. Intraoperative Radiotherapy for Breast Cancer: Its Perceived Simplicity. Oncology. Vol 27. No. 2. 2013 Feb 15.
- McCahill LE, Wagman LD, et al. Primary mFOLFOX6 + bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP Trial C-10. J Clin Oncol. 2012 Sep 10;30(26):3223-8. Epub 2012 Aug 6
- Forouzannia A, Harness JK, Carpenter MM, Ash RB, Gonzalez MM, Fischer S, Rodriguez A, Wagman LD. Intra-Operative Electron Radiotherapy (IOERT) Boost As A Component Of Adjuvant Radiation For Breast Cancer In The Community Setting. Am Surg. 2012 Oct;78(10):1071-4.